CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

203567Orig1s000

Trade Name:	Jublia topical solution, 10%
Generic Name:	efinaconazole
Sponsor:	Dow Pharmaceutical Sciences, Inc.
Approval Date:	June 6, 2014
Indications:	For the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

CENTER FOR DRUG EVALUATION AND RESEARCH

203567Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Summary Review	**X**
Officer/Employee List	**X**
Office Director Memo	**X**
Cross Discipline Team Leader Review	
Medical Review(s)	**X**
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	**X**
Statistical Review(s)	**X**
Microbiology / Virology Review(s)	**X**
Clinical Pharmacology/Biopharmaceutics Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	**X**
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203567Orig1s000

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203567

NDA APPROVAL

Dow Pharmaceutical Sciences, Inc.
Attention: Sean Humphrey
Manager, Regulatory Affairs
1330 Redwood Way
Petaluma, CA 94954

Dear Mr. Humphrey:

Please refer to your New Drug Application (NDA) dated and received on July 25, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Julia (efinaconazole) topical solution, 10%.

We acknowledge receipt of your amendments dated August 6, 10, and 20, September 26, October 17 and 22, December 6, 7, 14, 19 and 20, 2012; January 9 and 17, March 18 and 29, December 20, 2013; January 16, February 4, May 16, 23 and 27, June 4, 2014.

The December 20, 2013, submission constituted a complete response to our May 13, 2013, action letter.

This new drug application provides for the use of Julia (efinaconazole) topical solution, 10% for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, and text for the instructions for use). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.
The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).* Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 203567**." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ADVISORY COMMITTEE

Your application for Julia (efinaconazole) topical solution, 10% was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the drug in the diagnosis, cure, mitigation, treatment, or prevention of a disease.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 years to 11 years, 11 months because necessary studies are impossible or highly impracticable. There appears to be few culture positive cases of onychomycosis in subjects less than 12 years of age in the general population.

We are deferring submission of your pediatric study for ages 12 to less than 17 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the FDCA is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. This required study is listed below.

2156-1 A multicenter, randomized, double-blind study evaluating the safety, efficacy and pharmacokinetics of Julia (efinaconazole) topical solution, 10% versus vehicle in

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.